At the time of writing, Theravance Biopharma Inc [TBPH] stock is trading at $13.15, up 1.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TBPH shares have gain 14.15% over the last week, with a monthly amount glided 13.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Theravance Biopharma Inc [NASDAQ: TBPH] stock has seen the most recent analyst activity on August 06, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $10 from $15. Previously, BTIG Research started tracking the stock with Buy rating on April 12, 2024, and set its price target to $21. On January 08, 2024, downgrade downgraded it’s rating to In-line. SVB Leerink started tracking the stock assigning a Outperform rating and suggested a price target of $12 on May 23, 2022. JP Morgan upgraded its rating to a Neutral but $12 remained the price target by the analyst firm on November 05, 2021. JP Morgan downgraded its rating to Underweight for this stock on September 15, 2021, but kept the price target unchanged to $7. In a note dated August 25, 2021, Morgan Stanley downgraded an Underweight rating on this stock and revised its target price from $27 to $14.
For the past year, the stock price of Theravance Biopharma Inc fluctuated between $7.88 and $13.14. Currently, Wall Street analysts expect the stock to reach $15.33 within the next 12 months. Theravance Biopharma Inc [NASDAQ: TBPH] shares were valued at $13.15 at the most recent close of the market. An investor can expect a potential return of 16.58% based on the average TBPH price forecast.
Analyzing the TBPH fundamentals
According to Theravance Biopharma Inc [NASDAQ:TBPH], the company’s sales were 77.20M for trailing twelve months, which represents an 83.75% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -0.77%, Pretax Profit Margin comes in at -0.74%, and Net Profit Margin reading is -0.89%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.32 and Total Capital is -0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.87 points at the first support level, and at 12.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.34, and for the 2nd resistance point, it is at 13.53.
Ratios To Look Out For
It is important to note that Theravance Biopharma Inc [NASDAQ:TBPH] has a current ratio of 6.70. Further, the Quick Ratio stands at 6.70, while the Cash Ratio is 3.51. Considering the valuation of this stock, the price to sales ratio is 8.58, the price to book ratio is 2.95 and price to earnings (TTM) ratio is 56.22.
Transactions by insiders
Recent insider trading involved Farnum Rhonda, SVP, COMM & MEDICAL AFFAIRS, that happened on Jul 14 ’25 when 10000.0 shares were sold. Officer, RHONDA FARNUM completed a deal on Jul 14 ’25 to buy 10000.0 shares. Meanwhile, SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold 24000.0 shares on Jun 02 ’25.
